Overview

The enzyme-linked immunosorbent assay (ELISA) is a frequently used application which determines the concentration of an analyte in solution. The ELISA method is straightforward and rapid. With automated equipment the assay is easily scalable for set up in high-throughput and can handle a large number of samples in parallel, making it a popular choice for the evaluation of research and diagnostic targets.

ELISA Protocols

General ELISA Protocols

Standard methods for different types of ELISA in 96-well microtiter plate format, including recommended buffers.

  1. Indirect ELISA
  2. Competition (Inhibition) ELISA
  3. Direct ELISA with streptavidin-biotin detection
  4. Sandwich ELISA with streptavidin-biotin detection
  5. Sandwich ELISA with direct detection

Protocols for use with Anti-Biotherapeutic Antibodies

Bio-Rad’s anti-biotherapeutic antibodies are ideal for the measurement of monoclonal antibody drugs and biosimilar products in PK and ADA assays.

We have developed a range of highly specific, recombinant anti-idiotypic antibodies with different binding modes and properties, enabling the development of bridging ELISA and antigen capture ELISA. Protocols are available for each type of PK assay and ADA assay for many of the anti-biotherapeutic products in our catalog.


PK and ADA Bridging ELISA Protocols

Bridging ELISA is a special case of a sandwich ELISA in which a dimeric or oligomeric antigen (most often an antibody in a sample) is detected by a capture and detection antibody. The antigen bridges the two specific antibodies. Bridging ELISAs are most frequently used for the detection of IgG, for example in pharmacokinetic (PK) or anti-drug antibody (ADA) assays.

PK Bridging ELISA measuring free drug protocols

PK Bridging ELISA measuring free drug

Type 1 anti-idiotypic antibodies are inhibitory and are used to detect free drug

  1. Abatacept
  2. Adalimumab
  3. Bevacizumab
  4. Brentuximab vedotin
  5. Cemiplimab
  6. Cetuximab
  7. Daratumumab
  8. Denosumab
  9. Eculizumab
  10. Etanercept
  11. Golimumab
  12. Infliximab
  13. Ipilimumab
  14. Natalizumab
  15. Nivolumab
  16. Omalizumab
  17. Palivizumab
  18. Panitumumab
  19. Pembrolizumab
  20. Pertuzumab
  21. Rituximab
  22. Secukinumab
  23. Tocilizumab
  24. Trastuzumab (HCA166, HCA168)
  25. Trastuzumab  (HCA169, HCA176P)
  26. Trastuzumab (HCA169, HCA177P)
  27. Trastuzumab (HCA169, HCA270 IgG4)
  28. Ustekinumab  (HCA208, HCA210)
  29. Ustekinumab  (HCA209, HCA210)
  30. Vedolizumab 
PK Bridging ELISA measuring total drug protocols

PK Bridging ELISA measuring total drug

Type 2 anti-idiotypic antibodies are non-inhibitory and enable the measurement of total drug – free, partially and fully bound

  1. Cetuximab
  2. Etanercept
  3. Golimumab
  4. Infliximab
  5. Tocilizumab
ADA Bridging ELISA protocols

ADA Bridging ELISA

Type 1 anti-idiotypic antibodies are neutralizing and fully human; in immunoglobulin format they can be used as a control or calibrator as a surrogate for human ADAs

  1. Abatacept
  2. Adalimumab (IgG1)
  3. Adalimumab (IgE)
  4. Bevacizumab
  5. Brentuximab vedotin
  6. Cemiplimab
  7. Certolizumab pegol
  8. Cetuximab
  9. Daratumumab
  10. Denosumab
  11. Eculizumab
  12. Etanercept
  13. Infliximab
  14. Ipilimumab
  15. Natalizumab
  16. Nivolumab
  17. Omalizumab
  18. Palivizumab
  19. Panitumumab
  20. Pembrolizumab
  21. Pertuzumab
  22. Ranibizumab
  23. Rituximab
  24. Secukinumab
  25. Tocilizumab
  26. Trastuzumab
  27. Ustekinumab
  28. Vedolizumab

 


Antigen Capture ELISA Protocols

A third type of antibody that only detects drug bound to its target antigen is available for some of our specificities.

Protocols: PK Antigen Capture ELISA measuring bound drug exclusively

PK Antigen Capture ELISA measuring bound drug exclusively

A Type 3 antibody is used in an antigen capture ELISA to detect bound drug exclusively and avoids the bridging ELISA format

  1. Adalimumab
  2. Golimumab
  3. Ipilimumab HCA331
  4. Ipilimumab TZA001P
  5. Omalizumab
  6. Ranibizumab HCA304, HCA306, HCA307
  7. Ranibizumab HCA316P
  8. Secukinumab
  9. Trastuzumab


Technical Support

Technical Support